logo
Twitter
Discord
Email
logo
Seer, Inc.

Seer, Inc.

NASDAQ•SEER
CEO: Dr. Omid C. Farokhzad M.D., Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2020-12-04
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Contact Information
3800 Bridge Parkway, Suite 102, Redwood City, CA, 94065, United States
650-453-0000
seer.bio
Market Cap
$106.32M
P/E (TTM)
-1.3
38.2
Dividend Yield
--
52W High
$2.44
52W Low
$1.62
52W Range
33%
Rank54Top 78.1%
2.7
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Weak • 2.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2025

Financial Dashboard

Q3 2025 Data

Revenue

$4.12M+4.54%
4-Quarter Trend

EPS

-$0.32-8.57%
4-Quarter Trend

FCF

-$7.85M-51.90%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Revenue Growth 22% Nine months revenue reached $12.38M, marking a 22% increase compared to $10.17M previously reported.
Operating Expense Reduction Total operating expenses decreased 18% to $66.89M for nine months, driven by lower R&D and SG&A spending.
Gross Profit Improvement Gross profit grew 25% to $6.28M for the nine months, reflecting better cost management relative to revenue.
Cash Position Strengthened Cash, cash equivalents, and restricted cash totaled $45.50M as of September 30, 2025, up from $38.15M previously.

Risk Factors

Sustained Operating Losses Incurred net loss of $(57.61M) for nine months; management expects continued operating losses for the foreseeable future.
Large Accumulated Deficit Accumulated deficit reached $(450.0M) as of September 30, 2025, highlighting significant historical investment burn.
Commercialization Adoption Risk Success hinges on broad scientific and market acceptance of the Proteograph Suite, which may not develop as expected.
Reliance on Future Financing Liquidity requires raising additional capital through equity or debt issuance if current resources prove insufficient for growth.

Outlook

Proteograph Commercialization Focus Focus remains on growing adoption of the Proteograph Product Suite, expanding the installed base, and increasing utilization.
Class B Stock Conversion Date Class B common stock is set to automatically convert to Class A common stock on December 9, 2025.
R&D Investment Continuation Plan to continue investing in research and development for product enhancements and developing new products and applications.
International Infrastructure Buildout Continue building sales, marketing, and distribution infrastructure across EU, UK, and Asia-Pacific regions.

Peer Comparison

Revenue (TTM)

Monte Rosa Therapeutics, Inc.GLUE
$181.54M
+665.1%
Nurix Therapeutics, Inc.NRIX
$83.69M
+48.3%
Kymera Therapeutics, Inc.KYMR
$43.73M
-50.1%

Gross Margin (Latest Quarter)

Lyell Immunopharma, Inc.LYEL
100.0%
+0.0pp
C4 Therapeutics, Inc.CCCC
100.0%
+13.4pp
Monte Rosa Therapeutics, Inc.GLUE
83.6%
-16.4pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
KYMR$5.49B-20.6-33.4%7.6%
PHVS$1.63B-8.1-67.1%0.2%
GLUE$1.54B93.38.3%8.7%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1.4%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 25, 2026
|
EPS:-
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 6, 2025|
    Revenue: $4.12M+4.5%
    |
    EPS: $-0.32-8.6%
    Miss

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 6, 2025|
    Revenue: $4.05M+31.9%
    |
    EPS: $-0.33-5.7%
    Beat

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 13, 2025|
    Revenue: $4.21M+37.1%
    |
    EPS: $-0.34+6.3%
    Beat

  • Form 10-K/A - FY 2024

    Period End: Dec 31, 2024|Filed: Apr 30, 2025|
    Revenue: $13.95M-8.1%
    |
    EPS: $-1.39-3.0%
    Miss

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 3, 2025|Refer to amended data

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 6, 2024|
    Revenue: $3.94M+3.4%
    |
    EPS: $-0.35+6.1%
    Miss

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 8, 2024|
    Revenue: $3.07M-11.5%
    |
    EPS: $-0.35-5.4%
    Meet

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 8, 2024|
    Revenue: $3.07M-17.5%
    |
    EPS: $-0.32+0.0%
    Miss